Jidinum

Sitagliptin, the active ingredient in Jidinum, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to improve blood glucose control when combined with diet and exercise.

GNH USA supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation.

- Type 2 diabetes mellitus (monotherapy): improves glycemic control as a single oral agent. - Type 2 diabetes mellitus (combination therapy): enhances glucose lowering when added to metformin. - Type 2 diabetes mellitus (adjunct to insulin): reduces required insulin dose and helps achieve target HbA1c levels.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection. - Headache: transient cranial discomfort. - Upper respiratory infection: symptoms such as cough or sore throat. - Gastrointestinal upset: nausea, abdominal pain or dyspepsia. - Dizziness: occasional light‑headedness. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including angioedema or anaphylaxis. - Bullous pemphigoid: autoimmune skin blistering disorder. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

Before initiating sitagliptin therapy, consider the following safety measures.

- Renal function: assess creatinine clearance and adjust dose if necessary. - Hepatic function: monitor liver enzymes in patients with existing liver disease. - Cardiovascular disease: use with caution in patients with a history of heart failure. - Concomitant insulin or sulfonylureas: increased risk of hypoglycemia; monitor glucose closely. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: heightened risk of hypoglycemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase sitagliptin plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin): reduce sitagliptin exposure and effectiveness.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: possible additive hypotensive effect. - Diuretics: monitor renal function and electrolytes. - NSAIDs: may affect renal clearance of sitagliptin, especially in compromised patients.